We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noninvasive Hemoglobin Monitor Improves Patient Management

By LabMedica International staff writers
Posted on 07 Feb 2011
Print article
Image: The Rainbow ReSposable Sensor for the noninvasive measurement of hemoglobin blood levels (photo courtesy Masimo).
Image: The Rainbow ReSposable Sensor for the noninvasive measurement of hemoglobin blood levels (photo courtesy Masimo).
A device that that continuously measures blood hemoglobin levels is accurate in a clinical setting, and does not require phlebotomy.

The monitoring sensor is placed on the finger of the patient and it continually displays the level of hemoglobin in the blood - a critical parameter for those in intensive care units or undergoing surgery.

A study carried out at the Englewood Hospital and Medical Center (Englewood, NJ, USA), evaluated the accuracy of Rainbow ReSposable Sensor, for the noninvasive measurement of hemoglobin blood levels (SpHb). The measurement were made on nine intensive care unit (ICU) patients with critically low hemoglobin levels (ranging from 4.3 g/dL - 8.6 g/dL) and were compared with invasive blood samples drawn simultaneously and analyzed by a central laboratory. The SpHb levels were continuously displayed on a Radical-7 Pulse CO-Oximeter.

The results of the study showed a mean bias of 0.70 g/dL and a precision of 1.05 g/dL for SpHb, and when compared to reference laboratory, hemoglobin values demonstrated clinically acceptable agreement. The investigators concluded that the ability to measure hemoglobin noninvasively and continuously has the potential to facilitate the timely detection of changes in hemoglobin and thus improve patient blood-management decisions in patients with critically low hemoglobin. Both the Rainbow ReSposable Sensor and the Radical-7 Pulse CO-Oximeter are manufactured by Masimo, (Irvine, CA, USA). SpHb is available as part of the Masimo rainbow SET platform.

Anna Juhl, R.N., the lead investigator, said, "Two important elements of Patient Blood Management (PBM) are the management of postoperative blood loss with any resulting anemia, and only transfusing based on clinical and laboratory guided evidence. The results of this study show that Masimo SpHb may help aid clinicians in achieving the goals of PBM in a timely fashion with less blood loss to the patient." The study was presented at the Annual Critical Care Congress held January 15-19, 2011 in San Diego (CA, USA).

Related Links:

Englewood Hospital
Masimo



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test monitors blood levels of DNA fragments released by dying tumor cells (Photo courtesy of 123RF)

Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer

Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.